glp 1 compounded tirzepatide Concerns Surrounding GLP-1s Mount As Shortages of Tirzepatide, Semaglutide End Compounded Tirzepatide Microdose - bmiMD

TABLE 3 Effect of SPAE on liver functions of rats administered dexamethasone (mean SD, n = 6)

They have also been linked to more serious issues like thyroid cancer, pancreatitis, and gallbladder problems

With the right patient, support, and monitoring, GLP-1s are a valid part of a comprehensive care plan

TRIUMPH-2 studies obesity in adults with type 2 diabetes

The GLP-1 receptor agonist semaglutide reduces risks of kidney function loss, kidney failure, cardiovascular events, cardiovascular death and all-cause mortality in people with CKD and T2DM Ongoing clinical and mechanistic studies are expected to expand use of GLP-1 receptor agonists, GLP-1/GIP and other metabolic hormones for the treatment of CKD At the moment the most complete data is available for semaglutide from SUSTAIN-6 and FLOW trial which is the only trial with primary renal outcome in T2DM patients out of all GLP-1 RA Very good data for renal outcomes as secondary ones available for GLP-1 RAs dulaglutide and liraglutide and GLP-1/GIP RA tirzepatide, Very interesting and positive data from mechanistic REMODEL trial with semaglutide in T2DM patients presented but not yet published (reduced perirenal fat, rernal fibrosis and much more) Based on following excellent papers: #glp1 #gip #semaglutide #tirzepatide #liraglutide #dulaglutide #kidney #ckd #chronickidneydisease #cardiovascularcomplications Martin Haluzks Post -1 Incretins have an important role in glucose homeostasis, regulation of appetite, energy expenditure and immunity

Consequently, strategies that preserve lean mass during active GLP-1RA therapy and stabilize metabolic regulation during transition or withdrawal are essential components of sustainable obesity care